Stock ZYXI ZYNEX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zynex, Inc.

Equities

ZYXI

US98986M1036

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
11.21 USD +2.47% Intraday chart for Zynex, Inc. -1.49% +2.94%
Mar. 01 RBC Raises Price Target on Zynex to $15 From $13, Keeps Outperform Rating MT
Feb. 29 Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 257.7 468.2 351 521 369.2 357.9 - -
Enterprise Value (EV) 1 257.7 468.2 351 521 382.2 324.8 346.9 357.9
P/E ratio 28.1 x 51.8 x 20.6 x 31.6 x 40.3 x 23.2 x 12 x 8.37 x
Yield - - - - - - - -
Capitalization / Revenue 5.67 x 5.84 x 2.69 x 3.29 x 2 x 1.57 x 1.23 x 1.03 x
EV / Revenue 5.67 x 5.84 x 2.69 x 3.29 x 2.07 x 1.43 x 1.19 x 1.03 x
EV / EBITDA 21.2 x 34.2 x 13.2 x 18.5 x 17.2 x 10.6 x 6.6 x 5.2 x
EV / FCF 41.9 x -2,804 x 55.4 x - 23.1 x 25.4 x 14.4 x 8.32 x
FCF Yield 2.38% -0.04% 1.81% - 4.33% 3.93% 6.93% 12%
Price to Book 13.5 x 8.27 x 4.87 x - - - - -
Nbr of stocks (in thousands) 36,018 38,266 38,728 37,453 33,904 31,930 - -
Reference price 2 7.155 12.24 9.064 13.91 10.89 11.21 11.21 11.21
Announcement Date 2/27/20 2/25/21 2/24/22 3/13/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 45.47 80.12 130.3 158.2 184.3 227.4 290.3 346.8
EBITDA 1 12.14 13.67 26.67 28.09 22.26 30.63 52.58 68.8
EBIT 1 11.07 10.25 22.37 22.94 10.78 24.72 46.2 60.3
Operating Margin 24.34% 12.79% 17.16% 14.5% 5.85% 10.87% 15.91% 17.39%
Earnings before Tax (EBT) 1 11.94 10.15 22.27 22.2 12.58 22.97 42.72 61.6
Net income 1 9.492 9.074 17.1 17.05 9.732 17.16 32.03 46.2
Net margin 20.87% 11.33% 13.13% 10.78% 5.28% 7.55% 11.03% 13.32%
EPS 2 0.2546 0.2364 0.4400 0.4400 0.2700 0.4833 0.9375 1.340
Free Cash Flow 1 6.143 -0.167 6.34 - 16.55 12.77 24.03 43
FCF margin 13.51% -0.21% 4.87% - 8.98% 5.61% 8.28% 12.4%
FCF Conversion (EBITDA) 50.61% - 23.77% - 74.35% 41.68% 45.71% 62.5%
FCF Conversion (Net income) 64.72% - 37.07% - 170.06% 74.4% 75.03% 93.07%
Dividend per Share - - - - - - - -
Announcement Date 2/27/20 2/25/21 2/24/22 3/13/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 34.79 40.37 31.08 36.76 41.52 48.8 42.17 44.95 49.92 47.28 47.69 53.14 60.2 66.4 59.38
EBITDA 1 9.332 12.96 3.074 5.537 8.126 11.36 1.014 4.012 7.291 9.942 3.14 4.585 8.68 14.22 6.95
EBIT 1 8.046 11.59 1.906 4.364 6.558 10.11 0.284 2.713 5.485 2.298 1.843 3.59 7.237 12.05 4.55
Operating Margin 23.13% 28.7% 6.13% 11.87% 15.79% 20.72% 0.67% 6.04% 10.99% 4.86% 3.86% 6.76% 12.02% 18.15% 7.66%
Earnings before Tax (EBT) 1 8.028 11.56 1.982 4.149 6.352 9.715 1.602 4.096 4.95 1.931 1.421 3.135 6.781 11.59 4.15
Net income 1 6.107 8.894 1.377 3.346 4.873 7.452 1.569 3.354 3.594 1.215 1.087 2.348 5.094 8.738 3.11
Net margin 17.56% 22.03% 4.43% 9.1% 11.74% 15.27% 3.72% 7.46% 7.2% 2.57% 2.28% 4.42% 8.46% 13.16% 5.24%
EPS 2 0.1546 0.2300 0.0300 0.0800 0.1300 0.2000 0.0400 0.0900 0.1000 0.0400 0.0333 0.0700 0.1367 0.2367 0.1350
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/2/21 2/24/22 4/28/22 7/28/22 10/27/22 3/13/23 4/27/23 7/27/23 10/26/23 2/29/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 13 - - -
Net Cash position 1 - - - - - 33.1 11.1 -
Leverage (Debt/EBITDA) - - - - 0.5852 x - - -
Free Cash Flow 1 6.14 -0.17 6.34 - 16.6 12.8 24 43
ROE (net income / shareholders' equity) 65.2% 23.7% 23.1% - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 0.5300 1.480 1.860 - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.16 0.99 0.61 0.42 1.21 1.5 3.33 -
Capex / Sales 0.35% 1.23% 0.47% 0.26% 0.65% 0.66% 1.15% -
Announcement Date 2/27/20 2/25/21 2/24/22 3/13/23 2/29/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Zynex, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.21 USD
Average target price
18.98 USD
Spread / Average Target
+69.31%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
ZYNEX, INC. Stock Zynex, Inc.
+2.94% 358M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. ZYXI Stock
  4. Financials Zynex, Inc.